Prime Medicine, Inc. (PRME)
| Market Cap | 657.36M +24.7% |
| Revenue (ttm) | 4.07M -17.9% |
| Net Income | -187.89M |
| EPS | -1.09 |
| Shares Out | 177.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,117,441 |
| Open | 3.830 |
| Previous Close | 3.710 |
| Day's Range | 3.690 - 3.860 |
| 52-Week Range | 2.670 - 6.940 |
| Beta | 2.35 |
| Analysts | Buy |
| Price Target | 7.11 (+92.42%) |
| Earnings Date | Aug 6, 2026 |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in... [Read more]
Financial Performance
In 2025, Prime Medicine's revenue was $4.63 million, an increase of 55.28% compared to the previous year's $2.98 million. Losses were -$201.14 million, 2.69% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $7.11, which is an increase of 92.42% from the latest price.
News
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap...
Prime Medicine transferred with Buy rating at Chardan
Chardan analyst Keay Nakae keept a Buy rating on Prime Medicine (PRME) with a $7 price target following a transfer of coverage. The firm cites the potential of the company’s…
BMO starts Prime Medicine at Outperform into 2027 readouts
BMO Capital analyst David Lebowitz initiated coverage of Prime Medicine (PRME) with an Outperform rating and $9 price target The firm views Prime as a “differentiated” next-generation gene editing pla...
Prime Medicine initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Prime Medicine (PRME) with an Outperform rating and $9 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considered a…
Prime Medicine reports Q4 EPS (24c), consensus (26c)
Reports Q4 revenue $1.15M, consensus $1.11M. “We have continued to deliver on the focused strategy we laid out last year,” said Allan Reine, Chief Executive Officer of Prime Medicine (PRME).
Prime Medicine Quarterly report: Q2 2026
Prime Medicine has published its Q2 2026 quarterly earnings report on August 6, 2026.
Prime Medicine Earnings release: Q2 2026
Prime Medicine released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most p...
TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647
TD Cowen notes that Prime Medicine (PRME) announced a positive binding arbitration resolution with Beam Therapeutics (BEAM) over PM647 in alpha-1 antitrypsin deficiency, confirming PM647 is in Prime’s...
Resolution in favor of Prime has limited impact to Beam, says BofA
BofA analyst Alec Stranahan reiterated a Buy rating and $47 price target on Beam Therapeutics (BEAM) after Prime Medicine (PRME) announced a “positive” resolution to arbitration with Beam Therapeutics...
Prime Medicine reports positive resolution to arbitration with Beam Therapeutics
Prime Medicine (PRME) earlier announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics (BEAM) relating to the parties’ 2019 Collaboration and License Agr...
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damag...
Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today
20:12 EDT Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine (PRME) today
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Prime Medicine upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Prime Medicine (PRME) to Buy from Neutral with an $8 price target after the company announced that New Zealand’s Medicines and Medical Devices Safety Authority cleared the…
Prime Medicine granted RMAT designation for PM359
Prime Medicine (PRME) announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell thera...
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in p4...
Prime Medicine announces New Zealand cleared trial application for PM577a
Prime Medicine (PRME) announced that the New Zealand Medicines and Medical Devices Safety Authority has cleared the Company’s Clinical Trial Application for PM577a, an investigational Prime Editor for...
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North Ameri...
Prime Medicine Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Prime Editing technology has enabled genetic cures in CGD and is advancing in vivo programs for Wilson Disease and Alpha-1 antitrypsin deficiency, with clinical data expected in 2027. The pipeline leverages modular LNP delivery and differentiated PASSIGE technology, while strong IP and partnerships support financial stability and future growth.
Prime Medicine Transcript: AGM 2026
The meeting confirmed a quorum and approved the election of two directors and the ratification of the audit firm for 2026. No questions were raised by stockholders, and all proposals passed by the required majority.
Prime Medicine Transcript: Jefferies Global Healthcare Conference 2026
Prime Editing technology is advancing with global clinical trials for Wilson's disease and Alpha-1 antitrypsin deficiency, both targeting IND/CTA filings this year and initial data in 2027. Cystic fibrosis and broader liver indications are in preclinical stages, with key catalysts including arbitration resolution and a potential BLA filing for CGD.
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.